Tags : Cancer Therapies

Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer

Shots: Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the therapies. The first milestone is payable following IND submission Following a successful IND submission, Jazz will be responsible for further development, manufacturing, regulatory activities, and […]Read More

Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies

Shots: Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform, Ligand Design and Ligand Express The companies will design molecules […]Read More

Merck KGaA Collaborates with Personalis to Develop Novel Biomarkers for

Shots: Merck KGaA to utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT to evaluate novel biomarkers and mechanisms of resistance to cancer therapies The collaboration leads to the development of novel biomarker identification, analysis of therapy resistance mechanisms, patient stratification, combination therapy strategy and molecular categorization of cancer indications for enabling precision therapy Personalis’ ImmunoID NeXT […]Read More

The US FDA Initiates its First Step Towards Project Orbis

Shots: The US FDA announces Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) providing a framework concurrent submission and review of oncology therapies in collaboration with TGA and Health Canada, allowing for simultaneous decisions in all three countries The collaboration allows cancer patients to receive earlier access to products in other […]Read More